Bank of America’s Apellis Pharmaceuticals APLS Stock Holding History

Bank of America’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-80,000	Closed	-$4.79M	–	7713
2023 Q4	$4.79M	Sell	80,000 -48,200	-38%	-$2.45M	﹤0.01%	3588
2023 Q3	$4.88M	Buy	128,200 +112,100	+696%	+$4.92M	﹤0.01%	3430
2023 Q2	$1.47M	Buy	+16,100	New	+$1.39M	﹤0.01%	4479
2021 Q4	–	Sell	-106,500	Closed	-$3.51M	–	8189
2021 Q3	$3.51M	Buy	+106,500	New	+$5.98M	﹤0.01%	3916

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of America's APLS Position: Q2 2026 in Review

Bank of America sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,190,864 shares — an estimated $47.9M sold.

Bank of America first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $68.5M in Q1 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Bank of America reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Bank of America sold 1,190,864 Apellis Pharmaceuticals shares in Q2 2026, an estimated $47.9M.
Bank of America first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
Bank of America's Apellis Pharmaceuticals position peaked at $68.5M in Q1 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.